I agree. These results are hard to ignore and were so good that we got a late breaking at the CTAD.
The full data will be eye opening with actigrapghy, sleep measures and other secondary endpoints.
Depending on the strength of these, and there is no reason to believe they aren't strong, IMO the FDA and/or TGA will grant us some type of accelerated pathway.
Also agree that we will not here more until either the peer review is complete or a regulatory body has rendered a decision on whatever.
Whether it be a phase 3, AA, PA, BTD etc. They are all wins of varying degrees.